{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:12:53Z","timestamp":1765807973024,"version":"3.37.3"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T00:00:00Z","timestamp":1634342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T00:00:00Z","timestamp":1634342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"japan society for the promotion of science","doi-asserted-by":"publisher","award":["17K01470"],"award-info":[{"award-number":["17K01470"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Advanced glycation end-products, indicated by skin autofluorescence (SAF) levels, could be prognostic predictors of all-cause and cardiovascular mortality in patients with diabetes mellitus (DM) and renal disease. However, the clinical usefulness of SAF levels in patients with heart failure (HF) who underwent cardiac rehabilitation (CR) remains unclear. This study aimed to investigate the associations between SAF and MACE risk in patients with HF who underwent CR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study enrolled 204 consecutive patients with HF who had undergone CR at our university hospital between November 2015 and October 2017. Clinical characteristics and anthropometric data were collected at the beginning of CR. SAF levels were noninvasively measured with an autofluorescence reader. Major adverse cardiovascular event (MACE) was a composite of all-cause mortality and unplanned hospitalization for HF. Follow-up data concerning primary endpoints were collected until November 2017.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients\u2019 mean age was 68.1\u00a0years, and 61% were male. Patients were divided into two groups according to the median SAF levels (High and Low SAF groups). Patients in the High SAF group were significantly older, had a higher prevalence of chronic kidney disease, and more frequently had history of coronary artery bypass surgery; however, there were no significant between-group differences in sex, prevalence of DM, left ventricular ejection fraction, and physical function. During a mean follow-up period of 590\u00a0days, 18 patients had all-cause mortality and 36 were hospitalized for HF. Kaplan\u2013Meier analysis showed that patients in the high SAF group had a higher incidence of MACE (log-rank P\u2009&lt;\u20090.05). After adjusting for confounding factors, Cox regression multivariate analysis revealed that SAF levels were independently associated with the incidence of MACE (odds ratio, 1.86; 95% confidence interval, 1.08\u20133.12; P\u2009=\u20090.03).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>SAF levels were significantly associated with the incidence of MACE in patients with HF and may be useful for risk stratification in patients with HF who underwent CR.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12933-021-01398-0","type":"journal-article","created":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T20:12:29Z","timestamp":1634415149000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Relationship between skin autofluorescence levels and clinical events in patients with heart failure undergoing cardiac rehabilitation"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2149-1270","authenticated-orcid":false,"given":"Mitsuhiro","family":"Kunimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miho","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuro","family":"Aikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Ouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Fukao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuro","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abidan","family":"Abulimiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Honzawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akie","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taira","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Amano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Saitoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Morisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Daida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Minamino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,16]]},"reference":[{"issue":"2","key":"1398_CR1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jchf.2014.08.004","volume":"3","author":"A Dei Cas","year":"2015","unstructured":"Dei Cas A, Khan SS, Butler J, Mentz RJ, Bonow RO, Avogaro A, et al. Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. JACC Heart Fail. 2015;3(2):136\u201345.","journal-title":"JACC Heart Fail"},{"issue":"1","key":"1398_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ecl.2013.09.007","volume":"43","author":"JC Kovacic","year":"2014","unstructured":"Kovacic JC, Castellano JM, Farkouh ME, Fuster V. The relationships between cardiovascular disease and diabetes: focus on pathogenesis. Endocrinol Metab Clin North Am. 2014;43(1):41\u201357.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"4","key":"1398_CR3","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.cardiores.2004.05.001","volume":"63","author":"G Basta","year":"2004","unstructured":"Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res. 2004;63(4):582\u201392.","journal-title":"Cardiovasc Res"},{"issue":"6","key":"1398_CR4","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1089\/rej.2012.1335","volume":"15","author":"S Yamagishi","year":"2012","unstructured":"Yamagishi S. Potential clinical utility of advanced glycation end product cross-link breakers in age- and diabetes-associated disorders. Rejuvenation Res. 2012;15(6):564\u201372.","journal-title":"Rejuvenation Res"},{"issue":"7","key":"1398_CR5","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1007\/s00125-004-1451-2","volume":"47","author":"R Meerwaldt","year":"2004","unstructured":"Meerwaldt R, Graaff R, Oomen PHN, Links TP, Jager JJ, Alderson NL, et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia. 2004;47(7):1324\u201330.","journal-title":"Diabetologia"},{"issue":"18","key":"1398_CR6","doi-asserted-by":"publisher","first-page":"e009833","DOI":"10.1161\/JAHA.118.009833","volume":"7","author":"I Cavero-Redondo","year":"2018","unstructured":"Cavero-Redondo I, Soriano-Cano A, Alvarez-Bueno C, Cunha PG, Martinez-Hortelano JA, Garrido-Miguel M, et al. Skin autofluorescence-indicated advanced glycation end products as predictors of cardiovascular and all-cause mortality in high-risk subjects: a systematic review and meta-analysis. J Am Heart Assoc. 2018;7(18):e009833.","journal-title":"J Am Heart Assoc"},{"issue":"16","key":"1398_CR7","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","volume":"62","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147-239.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1398_CR8","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982\u201392.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"1398_CR9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12872-020-01484-3","volume":"20","author":"M Kunimoto","year":"2020","unstructured":"Kunimoto M, Shimada K, Yokoyama M, Matsubara T, Aikawa T, Ouchi S, et al. Association between the tissue accumulation of advanced glycation end products and exercise capacity in cardiac rehabilitation patients. BMC Cardiovasc Disord. 2020;20(1):195.","journal-title":"BMC Cardiovasc Disord"},{"issue":"3","key":"1398_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.4161\/derm.22028","volume":"4","author":"P Gkogkolou","year":"2012","unstructured":"Gkogkolou P, B\u00f6hm M. Advanced glycation end products: key players in skin aging? Dermatoendocrinol. 2012;4(3):259\u201370.","journal-title":"Dermatoendocrinol"},{"issue":"12","key":"1398_CR11","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.2337\/dc05-2173","volume":"29","author":"HL Lutgers","year":"2006","unstructured":"Lutgers HL, Graaff R, Links TP, Ubink-Veltmaat LJ, Bilo HJ, Gans RO, et al. Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care. 2006;29(12):2654\u20139.","journal-title":"Diabetes Care"},{"issue":"24","key":"1398_CR12","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","volume":"358","author":"A Patel","year":"2008","unstructured":"Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560\u201372.","journal-title":"N Engl J Med"},{"issue":"24","key":"1398_CR13","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"HC Gerstein","year":"2008","unstructured":"Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545\u201359.","journal-title":"N Engl J Med"},{"issue":"2","key":"1398_CR14","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa0808431","volume":"360","author":"W Duckworth","year":"2009","unstructured":"Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129\u201339.","journal-title":"N Engl J Med"},{"issue":"25","key":"1398_CR15","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1056\/NEJMoa052187","volume":"353","author":"DM Nathan","year":"2005","unstructured":"Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643\u201353.","journal-title":"N Engl J Med"},{"issue":"15","key":"1398_CR16","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577\u201389.","journal-title":"N Engl J Med"},{"issue":"9","key":"1398_CR17","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1253\/circj.CJ-19-0618","volume":"83","author":"SI Yamagishi","year":"2019","unstructured":"Yamagishi SI. Role of advanced glycation endproduct (AGE)-receptor for advanced glycation endproduct (RAGE) axis in cardiovascular disease and its therapeutic intervention. Circ J. 2019;83(9):1822\u20138.","journal-title":"Circ J"},{"issue":"8","key":"1398_CR18","doi-asserted-by":"publisher","first-page":"832","DOI":"10.2174\/092986607781483705","volume":"14","author":"S Yamagishi","year":"2007","unstructured":"Yamagishi S, Ueda S, Matsui T, Nakamura K, Imaizumi T, Takeuchi M, et al. Pigment epithelium-derived factor (PEDF) prevents advanced glycation end products (AGEs)-elicited endothelial nitric oxide synthase (eNOS) reduction through its anti-oxidative properties. Protein Pept Lett. 2007;14(8):832\u20135.","journal-title":"Protein Pept Lett"},{"issue":"11","key":"1398_CR19","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/j.1365-2443.2008.01234.x","volume":"13","author":"K Yoh","year":"2008","unstructured":"Yoh K, Hirayama A, Ishizaki K, Yamada A, Takeuchi M, Yamagishi S, et al. Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice. Genes Cells. 2008;13(11):1159\u201370.","journal-title":"Genes Cells"},{"issue":"12","key":"1398_CR20","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.ejheart.2007.09.009","volume":"9","author":"JW Hartog","year":"2007","unstructured":"Hartog JW, Voors AA, Bakker SJ, Smit AJ, van Veldhuisen DJ. Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart Fail. 2007;9(12):1146\u201355.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"1398_CR21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.cardfail.2006.11.009","volume":"13","author":"Y Koyama","year":"2007","unstructured":"Koyama Y, Takeishi Y, Arimoto T, Niizeki T, Shishido T, Takahashi H, et al. High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure. J Card Fail. 2007;13(3):199\u2013206.","journal-title":"J Card Fail"},{"issue":"5","key":"1398_CR22","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.ahj.2012.07.027","volume":"164","author":"S Willemsen","year":"2012","unstructured":"Willemsen S, Hartog JW, van Veldhuisen DJ, van der Meer P, Roze JF, Jaarsma T, et al. The role of advanced glycation end-products and their receptor on outcome in heart failure patients with preserved and reduced ejection fraction. Am Heart J. 2012;164(5):742-9.e3.","journal-title":"Am Heart J"},{"issue":"2","key":"1398_CR23","doi-asserted-by":"publisher","first-page":"462","DOI":"10.3390\/nu11020462","volume":"11","author":"A Sakasai-Sakai","year":"2019","unstructured":"Sakasai-Sakai A, Takata T, Takino JI, Takeuchi M. The relevance of toxic AGEs (TAGE) cytotoxicity to NASH pathogenesis: a mini-review. Nutrients. 2019;11(2):462.","journal-title":"Nutrients"},{"key":"1398_CR24","doi-asserted-by":"publisher","first-page":"739852","DOI":"10.1155\/2010\/739852","volume":"2010","author":"J Takino","year":"2010","unstructured":"Takino J, Yamagishi S, Takeuchi M. Cancer malignancy is enhanced by glyceraldehyde-derived advanced glycation end-products. J Oncol. 2010;2010:739852.","journal-title":"J Oncol"},{"issue":"11","key":"1398_CR25","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/modpathol.3800661","volume":"19","author":"P Morbini","year":"2006","unstructured":"Morbini P, Villa C, Campo I, Zorzetto M, Inghilleri S, Luisetti M. The receptor for advanced glycation end products and its ligands: a new inflammatory pathway in lung disease? Modern Pathol. 2006;19(11):1437\u201345.","journal-title":"Modern Pathol"},{"key":"1398_CR26","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ijcard.2015.03.167","volume":"185","author":"S Yamagishi","year":"2015","unstructured":"Yamagishi S, Fukami K, Matsui T. Evaluation of tissue accumulation levels of advanced glycation end products by skin autofluorescence: a novel marker of vascular complications in high-risk patients for cardiovascular disease. Int J Cardiol. 2015;185:263\u20138.","journal-title":"Int J Cardiol"},{"issue":"18","key":"1398_CR27","doi-asserted-by":"publisher","first-page":"e009833","DOI":"10.1161\/JAHA.118.009833","volume":"7","author":"I Cavero-Redondo","year":"2018","unstructured":"Cavero-Redondo I, Soriano-Cano A, \u00c1lvarez-Bueno C, Cunha PG, Mart\u00ednez-Hortelano JA, Garrido-Miguel M, et al. Skin autofluorescence-indicated advanced glycation end products as predictors of cardiovascular and all-cause mortality in high-risk subjects: a systematic review and meta-analysis. J Am Heart Assoc. 2018;7(18):e009833.","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"1398_CR28","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00125-009-1308-9","volume":"52","author":"HL Lutgers","year":"2009","unstructured":"Lutgers HL, Gerrits EG, Graaff R, Links TP, Sluiter WJ, Gans RO, et al. Skin autofluorescence provides additional information to the UK prospective diabetes study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia. 2009;52(5):789\u201397.","journal-title":"Diabetologia"},{"issue":"1","key":"1398_CR29","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2337\/dc06-1391","volume":"30","author":"R Meerwaldt","year":"2007","unstructured":"Meerwaldt R, Lutgers HL, Links TP, Graaff R, Baynes JW, Gans RO, et al. Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care. 2007;30(1):107\u201312.","journal-title":"Diabetes Care"},{"issue":"2","key":"1398_CR30","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00125-018-4769-x","volume":"62","author":"RP van Waateringe","year":"2019","unstructured":"van Waateringe RP, Fokkens BT, Slagter SN, van der Klauw MM, van Vliet-Ostaptchouk JV, Graaff R, et al. Skin autofluorescence predicts incident type 2 diabetes, cardiovascular disease and mortality in the general population. Diabetologia. 2019;62(2):269\u201380.","journal-title":"Diabetologia"},{"issue":"1","key":"1398_CR31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12902-020-00676-4","volume":"21","author":"HE Boersma","year":"2021","unstructured":"Boersma HE, van Waateringe RP, van der Klauw MM, Graaff R, Paterson AD, Smit AJ, et al. Skin autofluorescence predicts new cardiovascular disease and mortality in people with type 2 diabetes. BMC Endocr Disord. 2021;21(1):14.","journal-title":"BMC Endocr Disord"},{"issue":"4","key":"1398_CR32","doi-asserted-by":"publisher","first-page":"247","DOI":"10.14740\/cr1097","volume":"11","author":"T Hitsumoto","year":"2020","unstructured":"Hitsumoto T. Skin autofluorescence as a predictor of first heart failure hospitalization in patients with heart failure with preserved ejection fraction. Cardiol Res. 2020;11(4):247\u201355.","journal-title":"Cardiol Res"},{"issue":"3","key":"1398_CR33","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1161\/CIRCOUTCOMES.113.000221","volume":"6","author":"DH Smith","year":"2013","unstructured":"Smith DH, Thorp ML, Gurwitz JH, McManus DD, Goldberg RJ, Allen LA, et al. Chronic kidney disease and outcomes in heart failure with preserved versus reduced ejection fraction: the cardiovascular research network PRESERVE study. Circ Cardiovasc Qual Outcomes. 2013;6(3):333\u201342.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"7","key":"1398_CR34","doi-asserted-by":"publisher","first-page":"e1003163","DOI":"10.1371\/journal.pmed.1003163","volume":"17","author":"A Shardlow","year":"2020","unstructured":"Shardlow A, McIntyre NJ, Kolhe NV, Nellums LB, Fluck RJ, McIntyre CW, et al. The association of skin autofluorescence with cardiovascular events and all-cause mortality in persons with chronic kidney disease stage 3: a prospective cohort study. PLoS Med. 2020;17(7):e1003163.","journal-title":"PLoS Med"},{"issue":"2","key":"1398_CR35","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s11255-006-0064-8","volume":"38","author":"DS Silverberg","year":"2006","unstructured":"Silverberg DS, Wexler D, Iaina A, Steinbruch S, Wollman Y, Schwartz D. Anemia, chronic renal disease and congestive heart failure\u2014the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists. Int Urol Nephrol. 2006;38(2):295\u2013310.","journal-title":"Int Urol Nephrol"},{"issue":"10","key":"1398_CR36","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/j.amjcard.2015.02.024","volume":"115","author":"A Sharma","year":"2015","unstructured":"Sharma A, Lavie CJ, Borer JS, Vallakati A, Goel S, Lopez-Jimenez F, et al. Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure. Am J Cardiol. 2015;115(10):1428\u201334.","journal-title":"Am J Cardiol"},{"issue":"7","key":"1398_CR37","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1053\/euhj.1999.1882","volume":"21","author":"C Berry","year":"2000","unstructured":"Berry C, Clark AL. Catabolism in chronic heart failure. Eur Heart J. 2000;21(7):521\u201332.","journal-title":"Eur Heart J"},{"issue":"3","key":"1398_CR38","doi-asserted-by":"publisher","first-page":"E574","DOI":"10.1152\/ajpendo.00394.2001","volume":"282","author":"P Imbeault","year":"2002","unstructured":"Imbeault P, Tremblay A, Simoneau JA, Joanisse DR. Weight loss-induced rise in plasma pollutant is associated with reduced skeletal muscle oxidative capacity. Am J Physiol Endocrinol Metab. 2002;282(3):E574\u20139.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"6","key":"1398_CR39","first-page":"E971","volume":"277","author":"V Mohamed-Ali","year":"1999","unstructured":"Mohamed-Ali V, Goodrick S, Bulmer K, Holly JM, Yudkin JS, Coppack SW. Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am J Physiol. 1999;277(6):E971\u20135.","journal-title":"Am J Physiol"},{"issue":"2","key":"1398_CR40","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1253\/circj.CJ-12-1235","volume":"77","author":"K Okita","year":"2013","unstructured":"Okita K, Kinugawa S, Tsutsui H. Exercise intolerance in chronic heart failure\u2013skeletal muscle dysfunction and potential therapies. Circ J. 2013;77(2):293\u2013300.","journal-title":"Circ J"},{"issue":"14","key":"1398_CR41","doi-asserted-by":"publisher","first-page":"14416","DOI":"10.1364\/OE.18.014416","volume":"18","author":"M Koetsier","year":"2010","unstructured":"Koetsier M, Nur E, Chunmao H, Lutgers HL, Links TP, Smit AJ, et al. Skin color independent assessment of aging using skin autofluorescence. Opt Express. 2010;18(14):14416\u201329.","journal-title":"Opt Express"},{"issue":"5","key":"1398_CR42","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1089\/dia.2006.8.523","volume":"8","author":"DJ Mulder","year":"2006","unstructured":"Mulder DJ, Water TV, Lutgers HL, Graaff R, Gans RO, Zijlstra F, et al. Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: an overview of current clinical studies, evidence, and limitations. Diabetes Technol Ther. 2006;8(5):523\u201335.","journal-title":"Diabetes Technol Ther"},{"issue":"2","key":"1398_CR43","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1089\/dia.2010.0123","volume":"13","author":"MJ Noordzij","year":"2011","unstructured":"Noordzij MJ, Lefrandt JD, Graaff R, Smit AJ. Dermal factors influencing measurement of skin autofluorescence. Diabetes Technol Ther. 2011;13(2):165\u201370.","journal-title":"Diabetes Technol Ther"},{"issue":"8","key":"1398_CR44","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1093\/eurjhf\/hfr067","volume":"13","author":"JW Hartog","year":"2011","unstructured":"Hartog JW, Willemsen S, van Veldhuisen DJ, Posma JL, van Wijk LM, Hummel YM, et al. Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. Eur J Heart Fail. 2011;13(8):899\u2013908.","journal-title":"Eur J Heart Fail"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-021-01398-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-021-01398-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-021-01398-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T08:27:02Z","timestamp":1699691222000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-021-01398-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,16]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1398"],"URL":"https:\/\/doi.org\/10.1186\/s12933-021-01398-0","relation":{},"ISSN":["1475-2840"],"issn-type":[{"type":"electronic","value":"1475-2840"}],"subject":[],"published":{"date-parts":[[2021,10,16]]},"assertion":[{"value":"18 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the ethics committee of our institution and conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declared no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"208"}}